drugset / Trial / NCT02429089
Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck
NaSingle-groupOpen-labelTreatment
Summary
In this trial, the investigators would like to investigate the activity of LEE011 associated with cetuximab (standard of care for the SCCHN patients at this stade of the disease).
Timeline
- Start
- 2015-04
- Primary completion
- 2017-09-01
- Completion
- 2018-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribociclib | Small molecule | 400 mg | Oral |
| Subject | Ribociclib | Small molecule | 600 mg | Oral |